Lecanemab for Treatment of Early Alzheimer Disease
Neurology live - 05 May 2025Lecanemab for Treatment of Early Alzheimer Disease ...
lecanemab
Lecanemab for Treatment of Early Alzheimer Disease ...
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
Biogen - 15 Apr 2025Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union ...
Doctors can bring in new US-approved drug for early-stage Alzheimer’s disease
The Straits Times - 18 Nov 2024Doctors can bring in new US-approved drug for early-stage Alzheimer’s disease ...
Lecanemab Alzheimer's therapy approved in Europe
DW - 15 Apr 2025Lecanemab Alzheimer's therapy approved in Europe ...
Leqembi (lecanemab) is the first medicine that slows progression of early Alzheimer's disease to be authorized in the EU
Select Science - 29 Apr 2025Leqembi (lecanemab) is the first medicine that slows progression of early Alzheimer's disease to be authorized in the EU ...
Biogen partner Eisai cut US jobs. Now can it boost Alzheimer's drug sales?
Nikkei Asia - 04 May 2025Biogen partner Eisai cut US jobs. Now can it boost Alzheimer's drug sales? ...
Leqembi recommended for treatment of early Alzheimer’s disease
European Medicines Agency - 14 Nov 2024Leqembi recommended for treatment of early Alzheimer’s disease ...
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
PR Newswire - 13 Jan 2025FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease ...
Report shows effects of Alzheimer’s in KY, the disease ‘you can’t see’
Kentucky Lantern - 05 May 2025Report shows effects of Alzheimer’s in KY, the disease ‘you can’t see’ ...
Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?
News-Medical - 17 Feb 2025Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost? ...
Leqembi approved as first treatment to slow early Alzheimer’s progression
PharmaTimes - 16 Apr 2025Leqembi approved as first treatment to slow early Alzheimer’s progression ...
ARIA With Monoclonal Antibody Treatments for Alzheimer Disease
Neurology live - 05 May 2025ARIA With Monoclonal Antibody Treatments for Alzheimer Disease ...
Alzheimer’s drug lecanemab, EMA re-examining marketing authorisation
Euractiv - 02 Oct 2024Alzheimer’s drug lecanemab, EMA re-examining marketing authorisation ...
What is lecanemab?
Alzheimer's Society - 22 Aug 2024What is lecanemab? ...
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
Pharmaceutical Technology - 16 Apr 2025EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s ...
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
Biogen - 14 Apr 2025Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission ...
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
Biogen - 03 Mar 2025Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia ...
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease
Biogen - 28 Feb 2025The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease ...
European Commission Grants Marketing Authorization for Leqembi® (lecanemab)
Biogen - 15 Apr 2025European Commission Grants Marketing Authorization for Leqembi® (lecanemab) ...